Title:
Ｄｌｋ１－Ｄｉｏ３クラスターに位置するｍｉＲＮＡまたはそのバリアントを活性成分として含む、筋疾患またはカヘキシーの予防または処置のための医薬組成物
Document Type and Number:
Japanese Patent JP7158759
Kind Code:
B2
Abstract:
The present invention relates to a pharmaceutical composition for preventing or treating a muscular disease or cachexia, comprising, as an active ingredient, a miRNA located in Dlk1-Dio3 cluster or a variant thereof. In the present invention, it has been found that expression of miRNAs located in the Dlk1-Dio3 cluster is decreased as age increases. In particular, in a case where most of the miRNAs are over-expressed in fully differentiated myotubes, it has been confirmed that the diameter of the myotubes increases. In addition, also in a tumor-induced cachexia mouse model, it has been confirmed that cachexia was improved by inhibiting Atrogin-1 protein. Accordingly, the miRNA located in the Dlk1-Dio3 cluster or a variant thereof can be usefully utilized for the treatment and prevention of an Atrogin-1-dependent muscular disease and cachexia.
More Like This:
Inventors:
Kwon Gison
Lee Kampyo
Shin Yojin
Lee Bora
Lee Sung Min
Lee Kampyo
Shin Yojin
Lee Bora
Lee Sung Min
Application Number:
JP2020557109A
Publication Date:
October 24, 2022
Filing Date:
January 09, 2019
Export Citation:
Assignee:
AVENTI INC.
International Classes:
A61K31/7105; A61K35/76; A61K35/761; A61K48/00; A61P21/00
Foreign References:
| KR20160131938A | ||||
| CN102212517A |
Attorney, Agent or Firm:
Yamato Kento
Yasushi Ochiai
Yasushi Ochiai